Drug
Ospemifene clinical trials
Also written Osphena®.
- studies test it
- 10
- open now
- 0
- in phase 3
- 6
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 1
- Phase 3
- 6
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Shionogi (7) · Hospital Clinic of Barcelona (1) · Sue Goldstein (1) · Emory University (1)
Studies
Open first, then newest update. How each study uses Ospemifene is read from its arms, and is right about nine times in ten.
Testing it · 10
- Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal DisordersCompletedPhase 4Hospital Clinic of BarcelonaNCT04677491Written as Ospemifene 60 mg
- Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVACompletedPhase 4Sue GoldsteinNCT02784613Written as Ospemifene
- Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to MenopauseCompletedPhase 3ShionogiNCT02638337Written as Ospemifene
- Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact UterusCompletedPhase 3ShionogiNCT01585558Written as Ospemifene (Dose 1)
- Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a UterusCompletedPhase 3ShionogiNCT01586364Written as Ospemifene 60Mg Oral Tablet
- A Clinical Study to Evaluate the Safety of OspemifeneCompletedPhase 3ShionogiNCT00566982Written as Ospemifene 60 mg
- Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual ActivityCompletedPhase 3ShionogiNCT00729469Written as Ospemifene 60 mg
- Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual DysfunctionTerminatedPhase 4Emory UniversityNCT03018106Written as Ospemifene
- A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal WomenCompletedPhase 3ShionogiNCT00276094Written as Ospemifene 30 mg
- A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal WomenCompletedPhase 2ShionogiNCT00630539Written as Ospemifene 5 mg
Codes
What other systems call Ospemifene · ClinicalTrials.gg INT004151
- MeSH (NLM) C119141OspemifeneConfirmed NLM, Wikidata
- UNII (FDA) B0P231ILBKOSPEMIFENEConfirmed FDA, NLM, Wikidata
- RxNorm 1370971Confirmed FDA, Wikidata
- Wikidata Q7107372ospemifeneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76958OspemifeneOne source FDA
- DrugBank DB04938One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C119141 | Ospemifene | Confirmed NLM, Wikidata |
| UNII (FDA) | B0P231ILBK | OSPEMIFENE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1370971 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7107372 | ospemifene | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76958 | Ospemifene | One source FDA |
| DrugBank | DB04938 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.